2026-01-18 - Analysis Report
# Abbott Laboratories (ABT) Analysis Report
## Overview
Abbott Laboratories is a leading global healthcare company that develops, manufactures, and commercializes products that help people live healthier, fuller lives.

## Return Rate Comparison
- **Review Stock (ABT)**: Cumulative return = 32.54%
- **Comparison Stock (VOO, S&P 500)**: Cumulative return = 93.36%
- **Divergence**: -60.82% (difference in cumulative return)

## Historical Data Analysis | Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 32.0% | 14.5% | 29.0% | 1.1 | $125.9B |
| 2017-2019  | 41.0% | 14.5% | 24.0% | 1.0 | $151.2B |
| 2018-2020  | -1.0% | 16.8% | -22.0% | 0.9 | $190.6B |
| 2019-2021  | 42.0% | 16.8% | -2.0% | 0.8 | $244.9B |
| 2020-2022  | -20.0% | 28.8% | -18.0% | 0.8 | $191.1B |
| 2021-2023  | -22.0% | 28.8% | -23.0% | 0.7 | $191.6B |
| 2022-2024  | -31.0% | 24.3% | -50.0% | 0.7 | $196.9B |
| 2023-2025  | 10.0% | 16.0% | -52.0% | 0.3 | $218.1B |

## Recent Stock Price Fluctuations
### SMA Analysis
- **Close**: $121.76
- **Last-Market**: $121.76
- **5-day SMA**: $123.85
- **20-day SMA**: $125.12
- **60-day SMA**: $125.91

## Technical Indicator Analysis
### RSI, PPO, and MRI
- **Market Risk Indicator (MRI)**: 0.80 (Medium Investment Recommended)
- **Relative Strength Index (RSI)**: 39.06
- **Price and Percent Oscillator (PPO)**: -0.24
- **Recent (20 days) relative divergence change**: -3.60 (worsening)
- **7-day Rank change**: 0 (flat)
- **7-day Dynamic Expected Return change**: 0.00 (flat)

## Technical Signal
- **Hybrid Signal**: Buy (Cash 0%)

## Expected Return
- **Expected Return (%)**: -1606.10% (excess return compared to S&P 500 if invested long-term)

## Recent News & Significant Events
### Headlines
- Is Abbott Laboratories (ABT) Price Weakness Creating A Potential Opportunity Now? - Yahoo Finance
- Abbott Laboratories (NYSE:ABT) Stands Out as a Dependable Dividend Stock for Income Investors - Chartmill
- Fund Update: New $84.6M $ABT stock position opened by Compagnie Lombard Odier SCmA - Quiver Quantitative
- How to listen as Abbott breaks down its latest quarterly results Jan. 22 - Stock Titan
- Absolute Software Co. (ABT.TO) (TSE:ABT) Stock Crosses Above Two Hundred Day Moving Average - Here's Why - MarketBeat
- Investors - Abbott

## Analyst Opinions
### Summary
- **Key**: Buy
- **Mean (1=StrongBuy~5=Sell)**: 1.71 (~Buy)
- **Opinions**: 25
- **Target Price (avg/high/low)**: $144.75 / $169.00 / $122.00

## Recent Earnings Analysis
### Quarterly EPS and Revenue Data
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-29 | $0.94 | $11.37 B |
| 2025-07-30 | $1.02 | $11.14 B |
| 2025-04-30 | $0.76 | $10.36 B |
| 2024-10-31 | $0.94 | $10.63 B |
| 2025-10-29 | $0.94 | $10.63 B |

## Financial Information
### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.37B | 55.36% |
| 2025-06-30 | $11.14B | 56.44% |
| 2025-03-31 | $10.36B | 56.86% |
| 2024-12-31 | $10.97B | 54.97% |
| 2024-09-30 | $10.63B | 55.83% |

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $50.95B | 3.23% |
| 2025-06-30 | $50.56B | 3.52% |
| 2025-03-31 | $48.81B | 2.71% |
| 2024-12-31 | $47.66B | 19.36% |
| 2024-09-30 | $39.80B | 4.14% |

## Comprehensive Analysis
Abbott Laboratories (ABT) has shown a significant divergence in its return rate compared to the S&P 500 (VOO). The recent stock price fluctuations indicate a weakness in the market, but the SMA analysis suggests a possible rebound. The technical indicator analysis shows a Medium Investment Recommended risk level. The expected return is significantly lower than the S&P 500. Recent news and significant events suggest a potential opportunity for investors. Analyst opinions recommend a Buy rating with a moderate target price. The quarterly earnings analysis shows a decline in revenue but a significant increase in profit margin. The capital and profitability analysis shows an increase in equity and a moderate return on equity. Overall, Abbott Laboratories (ABT) presents a mixed picture, but the technical indicators suggest a possible rebound.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.